QN-139b

N/A

Report date: 2025/07/18 16:10:48

Base Information

Drug NameQN-139b
Drug Alias NameQN-139b
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsNatural killer cell replacements
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsScleroderma, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Qihan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Qihan Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A